ArticleGigaScience2026
NEXT-scASV: a Nextflow pipeline for allele-specific variant calling from single-cell RNA-seq data.
Article in GigaScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NEXT-scASV: a Nextflow pipeline for allele-specific variant calling from single-cell RNA-seq data.GigaScience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The rapid accumulation of single-cell sequencing data presents major computational challenges in reproducibility, scaling, and handling data characteristics such as sparsity and technical variations, which complicate even basic analyses. The next level of complexity is the allele-specific analysis, focused on identifying differential gene expression or regulation between homologous chromosomes by estimating the allelic imbalance of read counts at individual single-nucleotide variants. Here, we present NEXT-scASV, a scalable Nextflow pipeline for calling allele-specific variants (ASVs) from 5' single-cell RNA sequencing data. NEXT-scASV automates the entire process-from read alignment and quality control to variant calling and statistical evaluation of the allelic imbalance-within a containerized environment, ensuring reproducibility and ease of deployment across platforms. NEXT-scASV is able to perform de novo ASV detection from single-cell sequencing data without prior genotyping. Its modular design allows for massive parallelization, efficiently handling the scale of modern atlas-level studies. We validate NEXT-scASV on a dataset of 135,000 peripheral blood mononuclear cells from 57 donors, demonstrating that it processes large-scale data efficiently, completing analysis in a week on a cluster with one node and 100 threads. Crucially, the pipeline reliably identifies ASVs even in rare cell populations (e.g., gdT GZMBhi and memory B IGHMhi cells), which remains elusive for bulk analyses. We also successfully detect allele-specific regulation of long non-coding RNAs and other lowly expressed, cell type-specific genes. Genes linked to detected ASVs show a high concordance (80%) with previously reported eQTLs. This strong validation confirms that NEXT-scASV produces biologically relevant results, making it a powerful tool for uncovering allele-specific regulation in large-scale, complex single-cell studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.